The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics ...

The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can ach ...

Q3 2025 Management View CEO Jean-Pierre Sommadossi reported "significant progress and achievements" this quarter, ...

Consolidated Lithium Metals Inc. (TSXV: CLM | FRA: Z36) ("CLM" or the "Company") is pleased to announce that it has entered into on November 17, 2025 a binding ...

Faraday Copper Corp. announces its financial results for the three and nine months ended 30, 2025. Highlights Year to Date Announced initiation of the largest ever drill program at the Copper Creek ...

Silexion continues to advance operational readiness for its planned Phase 2/3 clinical trials of SIL204, with toxicology ...

Facility completion marks a major milestone as equipment procurement and installation begin; exploration planning accelerates ...

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation ...

Upon satisfaction of these conditions and acquisition by the Company of the initial 60% undivided interest in the Project, CLM and SOQUEM will form a joint venture in respect of the Project to be ...

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver ...

Protests erupt in West Bengal and Jharkhand as locals fear losing livelihoods to new solar power projects at Panchet Dam.

Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase 2 ...